Variability in the Definition and Reporting of Adverse Events in Suicide Prevention Trials: An Examination of the Issues and a Proposed Solution

被引:6
作者
Oquendo, Maria A. [1 ]
Feldman, Sarah [1 ]
Silverman, Emily [1 ]
Currier, Dianne [2 ]
Brown, Gregory K. [3 ]
Chen, Donna [4 ]
Chiapella, Page [5 ]
Fischbach, Ruth [1 ]
Gould, Madelyn [1 ]
Stanley, Barbara [1 ]
Strauss, David [1 ]
Zelazny, Jamie [6 ]
Pearson, Jane [7 ]
机构
[1] New York State Psychiat Inst & Hosp, New York, NY 10032 USA
[2] Columbia Univ, Dept Psychiat, New York, NY USA
[3] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA
[4] Univ Virginia, Ctr Biomed Eth & Humanities, Charlottesville, VA USA
[5] NIAAA, Bethesda, MD USA
[6] Univ Pittsburgh, Pittsburgh, PA USA
[7] NIMH, Bethesda, MD 20892 USA
关键词
Adverse Events; safety; Serious Adverse Events; study evaluation; suicide research; TOWER-OF-BABEL; CLINICAL-TRIALS; SAFETY; INTERVENTION; NOMENCLATURE; MULTICENTER; IMPROVEMENT; BEHAVIOR; LESSONS; CARE;
D O I
10.1080/13811118.2011.541146
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Adverse events (AEs) and serious adverse events (SAEs) are important outcomes of any intervention study yet are under-researched. Vague and variable definitions and substantial underreporting make comparisons of risk between studies difficult and evaluation of the safety of a particular intervention almost impossible. These realities may deter researchers from studying at-risk populations. Suicidal behavior is an adverse event in any study, and potentially a very serious one. Thus the issues of reporting and definition are particularly salient for researchers who work with populations at risk for suicidal behavior, especially when the suicidal behavior is the outcome of interest. We conducted a qualitative study with experienced suicide researchers and intervention experts to delineate the issues related to reporting serious adverse events faced by investigators conducting trials in suicide prevention. Participants from multiple sites were interviewed by phone, interviews transcribed and coded for definition and reporting issues and suggested solutions. A narrative synthesis was prepared and validated by all participants. Participants highlighted the difficulties in defining AEs and SAEs and stressed the importance and complexity of ensuring the AE was related to the study and reported properly, and were in agreement about the consequences of AEs to both institutions and individuals. Participants identified the need for the development of clear and consistent AE definitions and reporting requirements. Clear and consistently applied definitions of adverse and serious adverse events and reporting requirements would enhance the comparability of intervention studies in suicidal populations.
引用
收藏
页码:29 / 42
页数:14
相关论文
共 50 条
  • [31] Variability in the Reporting Terminology of Adverse Events and Complications in Ankle Fracture Fixation: A Systematic Review
    St George, Stefan A.
    Sadr, Hooman
    Angthong, Chayanin
    Penner, Murray
    Salat, Peter
    Wing, Kevin
    Younger, Alistair S. E.
    Veljkovic, Andrea
    FOOT & ANKLE INTERNATIONAL, 2020, 41 (02) : 170 - 176
  • [32] Quality Assessment for Reporting Complications and Adverse Events in Spinal Surgery: A Proposed 5-Item Checklist
    Vildoza, Santiago
    Cabrera, Juan Pablo
    Guiroy, Alfredo
    Carazzo, Charles
    Gagliardi, Martin
    Joaquim, Andrei Fernandes
    Camino-Willhuber, Gaston
    WORLD NEUROSURGERY, 2022, 158 : E423 - E428
  • [33] Quality of serious adverse events reporting to academic sponsors of clinical trials: far from optimal
    Crepin, Sabrina
    Villeneuve, Claire
    Merle, Louis
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (06) : 719 - 724
  • [34] Monitoring and reporting adverse events in pragmatic clinical trials testing nonpharmacological pain management interventions
    Burns, Amy
    Young-McCaughan, Stacey
    Davis, Alison F.
    Vining, Robert
    Ali, Joseph
    Fritz, Julie M.
    Morasco, Benjamin J.
    Rhon, Daniel, I
    Roogow, Robert
    Kyriakides, Tassos C.
    Kerns, Robert D.
    PAIN MEDICINE, 2024, 25 : S64 - S67
  • [35] Reporting of adverse events, conflict of interest and funding in randomised controlled trials of antibiotics: a secondary analysis
    Bakhit, Mina
    Jones, Mark
    Baker, Jenalle
    Nair, Ramil
    Yan, Kylie
    Del Mar, Chris
    Scott, Anna Mae
    BMJ OPEN, 2021, 11 (07):
  • [36] Safety of biological drugs in rheumatoid arthritis: An assessment of quality of reporting of adverse events in randomised controlled trials
    Hadi, Muhammad
    McHugh, Gretl
    Conaghan, Philip
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2017, 69 : 5 - 6
  • [37] Understanding the Medical Dictionary for Regulatory Activities (MedDRA) reporting of herpes simplex virus (HSV) adverse events in atopic dermatitis clinical trials
    Tao, Rachel E.
    Pixley, Jessica N.
    Kontzias, Christina L.
    Feldman, Steven R.
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2023, 316 (01)
  • [38] Assessment of serious adverse events reporting by investigational centers in academic clinical trials: Cross-sectional survey and suggestions for improvement measures
    Cordeiro, L.
    Colin, A. L.
    Olivier, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 118 - 118
  • [39] Understanding the Medical Dictionary for Regulatory Activities (MedDRA) reporting of herpes simplex virus (HSV) adverse events in atopic dermatitis clinical trials
    Rachel E. Tao
    Jessica N. Pixley
    Christina L. Kontzias
    Steven R. Feldman
    Archives of Dermatological Research, 316
  • [40] Reporting adverse events in cancer surgery randomized trials: A systematic review of published trials in oesophago-gastric and gynecological cancer patients
    Meghelli, Leila
    Narducci, Fabrice
    Mariette, Christophe
    Piessen, Guillaume
    Vanseymortier, Marie
    Leblanc, Eric
    Collinet, Pierre
    Duhamel, Alain
    Penel, Nicolas
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 104 : 108 - 114